Lynn M. Schuchter, MD
Director, Tara Miller Melanoma Center at Penn Medicine, Philadelphia
Highlights
- LBBC Medical Advisory Board member since 2023
- Immediate past president of the American Society of Clinical Oncology
- Passionate about mentoring junior faculty, especially women
Lynn M. Schuchter, MD, is a board-certified medical oncologist specializing in melanoma, a type of skin cancer. She was also the 60th president of the American Society of Clinical Oncology, ending her term as president in the summer of 2024.
At the Tara Miller Melanoma Center, Dr. Schuchter works with an interdisciplinary oncology team to comprehensively treat people diagnosed with melanoma using molecularly targeted therapies. Her clinical research focuses on the development of new treatments.
Dr. Schuchter is passionate about mentoring junior faculty, especially women.
Experience & accolades
Expertise
- Medical oncology
- Melanoma
Education
- Hospital of the University of Pennsylvania
- Fellowship
- Johns Hopkins Hospital
- Fellowship
- Michael Reese Hospital
- Residency
- Chicago Medical School
- Doctor of medicine
Experience
- Tara Miller Melanoma Center, Penn Medicine (Present)
- Director
- American Society of Clinical Oncology (2023-2024)
- President
- Abramson Cancer Center, Penn Medicine (2008-2023)
- Chief, division of hematology/oncology
Awards & distinctions
- Hologic, Inc.’s Endowed Women Who Conquer Cancer mentorship award, from the ASCO Foundation, 2019
- Philadelphia Magazine’s Top Doctors, 2004-2021
- America’s Top Doctors, 2007, 2008, 2010-2018
- Best Doctors in America, 2003-2018
- Main Line Today’s Top Doctors, 2016
Professional memberships & board positions
- Living Beyond Breast Cancer Medical Advisory Board
- American Society of Clinical Oncology
Publications
- “A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy,” Clinical Cancer Research, 2024
- “Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk,” JAMA Oncology, 2024
- “FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma,” Clinical Cancer Research, 2024
- “Antigen-specific profiling for neoadjuvant anti-PD-1 therapy in melanoma,” Journal of Clinical Oncology, 2024